Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02293733
What this trial is testing

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
NSCLC Non Small Cells Lung Cancer
Groupe Francais De Pneumo-Cancerologie 144
Testing effectiveness (Phase 2)UnknownNCT03126799
What this trial is testing

Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
National Cancer Center, Korea 128
Post-approval studies (Phase 4)Study completedNCT01287754
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 24
Not applicableUnknownNCT02804217
What this trial is testing

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Who this might be right for
Non-small Cell Lung CancerAquired ResistanceEGFR TKIs
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)UnknownNCT04425681
What this trial is testing

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

Who this might be right for
Leptomeningeal MetastasisNon-small Cell Lung CancerEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 20
Large-scale testing (Phase 3)UnknownNCT02929693
What this trial is testing

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Who this might be right for
Cancer
Shanghai University of Traditional Chinese Medicine 198
Testing effectiveness (Phase 2)Study completedNCT04764214
What this trial is testing

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Who this might be right for
NSCLC Stage IVEGFR Activating Mutation
Fudan University 61
Testing effectiveness (Phase 2)Study completedNCT01532089
What this trial is testing

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
EGFR Exon 19 Deletion MutationEGFR NP_005219.2:p.L858RLung Non-Squamous Non-Small Cell Carcinoma+1 more
Academic and Community Cancer Research United 88
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Study completedNCT01941654
What this trial is testing

ATOM_local Ablative Therapy

Who this might be right for
NSCLCActivating EGFR Mutation
Chinese University of Hong Kong 18
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Not applicableEnrolling By InvitationNCT06730477
What this trial is testing

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 500
Testing effectiveness (Phase 2)Study completedNCT05146219
What this trial is testing

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Who this might be right for
NSCLCEGFR Activating MutationBrain Metastases+1 more
TYK Medicines, Inc 29
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Large-scale testing (Phase 3)WithdrawnNCT03529084
What this trial is testing

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Who this might be right for
Carcinoma, Non-small Cell Lung
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT04148898
What this trial is testing

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Who this might be right for
Leptomeningeal MetastasisNon-small Cell Lung CancerEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 80
Testing effectiveness (Phase 2)Ended earlyNCT00988169
What this trial is testing

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 6
Next Page